Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Marc Kahn who wrote (209)	7/4/1998 12:08:00 PM
From: Marc Kahn	Read Replies (1) \| Respond to of 534

According to a 6/30 filing with the SEC, sec.gov , the Aries/Paramount group has sold 400,000+ BJCT shares during the period from 5/11 through 6/25, for between $1.70 and $1.813. However, on 6/11 they exercised 500,000 warrants at $1.00 per share, providing Bioject with working capital. The net results: Aries/Paramount is realizing some nice profits Bioject is getting a cash infusion The market is being supplied with stock, keeping the share price down I noticed some large blocks on the sell side Thursday. Maybe there's more of this going on. The market seems to be able to absorb this supply without too much damage. Marc Kahn